(BWXT) BWX Technologies - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US05605H1005
Stock: Nuclear Components, Reactor Fuel, Valves, Steam Generators, Radioisotopes
Total Rating 79
Risk 83
Buy Signal 0.26
| Risk 5d forecast | |
|---|---|
| Volatility | 47.2% |
| Relative Tail Risk | -12.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.77 |
| Alpha | 78.86 |
| Character TTM | |
|---|---|
| Beta | 1.032 |
| Beta Downside | 1.331 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.87% |
| CAGR/Max DD | 1.49 |
EPS (Earnings per Share)
Revenue
Description: BWXT BWX Technologies March 01, 2026
BWX Technologies (BWXT) designs, manufactures, and services a broad portfolio of nuclear-related hardware and engineering solutions for government, commercial, and medical markets. Its operations are split between Government Operations-focused on naval nuclear components, defense-grade fuel, and uranium down-blending-and Commercial Operations, which supplies steam generators, fuel handling systems, and medical radioisotopes. The firm also offers lifecycle engineering services, from 3-D thermal-hydraulic analysis to in-plant inspection and non-destructive testing.
In its latest quarter (Q4 2025), BWXT reported revenue of $1.22 billion, a 9 % YoY increase, and GAAP earnings per share of $0.68, driven by a 12 % rise in its order backlog to $2.34 billion. The backlog is heavily weighted toward U.S. Department of Energy contracts for next-generation small modular reactors (SMRs), a segment expected to benefit from the administration’s $2.5 billion nuclear modernization budget. Additionally, the company’s medical isotopes division saw a 15 % volume uptick as demand for targeted radiopharmaceuticals expands globally.
For a deeper dive into BWXT’s valuation metrics and how these trends may affect its upside, consider exploring the analysis on ValueRay.
Headlines to watch out for
- Government contract awards drive naval nuclear component revenue
- Commercial nuclear power demand impacts steam generator sales
- Medical radioisotope production expands healthcare segment
- Uranium prices influence fuel fabrication costs
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 329.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.96 > 1.0 |
| NWC/Revenue: 27.77% < 20% (prev 16.86%; Δ 10.92% < -1%) |
| CFO/TA 0.11 > 3% & CFO 479.8m > Net Income 329.0m |
| Net Debt (1.51b) to EBITDA (551.5m): 2.74 < 3 |
| Current Ratio: 2.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.9m) vs 12m ago -0.04% < -2% |
| Gross Margin: 22.87% > 18% (prev 0.24%; Δ 2263 % > 0.5%) |
| Asset Turnover: 89.57% > 50% (prev 94.21%; Δ -4.63% > 0%) |
| Interest Coverage Ratio: 10.01 > 6 (EBITDA TTM 551.5m / Interest Expense TTM 44.2m) |
Altman Z'' 4.99
| A: 0.21 (Total Current Assets 1.56b - Total Current Liabilities 672.0m) / Total Assets 4.27b |
| B: 0.59 (Retained Earnings 2.52b / Total Assets 4.27b) |
| C: 0.12 (EBIT TTM 442.3m / Avg Total Assets 3.57b) |
| D: 0.82 (Book Value of Equity 2.51b / Total Liabilities 3.04b) |
| Altman-Z'' Score: 4.99 = AAA |
Beneish M -2.75
| DSRI: 1.05 (Receivables 944.9m/763.7m, Revenue 3.20b/2.70b) |
| GMI: 1.06 (GM 22.87% / 24.24%) |
| AQI: 1.14 (AQ_t 0.26 / AQ_t-1 0.23) |
| SGI: 1.18 (Revenue 3.20b / 2.70b) |
| TATA: -0.04 (NI 329.0m - CFO 479.8m) / TA 4.27b) |
| Beneish M-Score: -2.75 (Cap -4..+1) = A |
What is the price of BWXT shares?
As of March 11, 2026, the stock is trading at USD 195.91 with a total of 815,734 shares traded.
Over the past week, the price has changed by -4.82%, over one month by -1.96%, over three months by +9.05% and over the past year by +104.40%.
Over the past week, the price has changed by -4.82%, over one month by -1.96%, over three months by +9.05% and over the past year by +104.40%.
Is BWXT a buy, sell or hold?
BWX Technologies has received a consensus analysts rating of 4.27.
Therefore, it is recommended to buy BWXT.
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BWXT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 230.9 | 17.9% |
| Analysts Target Price | 230.9 | 17.9% |
BWXT Fundamental Data Overview March 07, 2026
P/E Trailing = 54.6089
P/E Forward = 49.0196
P/S = 5.5895
P/B = 15.2524
P/EG = 1.6728
Revenue TTM = 3.20b USD
EBIT TTM = 442.3m USD
EBITDA TTM = 551.5m USD
Long Term Debt = 2.02b USD (from longTermDebt, last quarter)
Short Term Debt = 8.80m USD (from shortTermDebt, last quarter)
Debt = 2.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.51b USD (from netDebt column, last quarter)
Enterprise Value = 19.39b USD (17.88b + Debt 2.02b - CCE 502.9m)
Interest Coverage Ratio = 10.01 (Ebit TTM 442.3m / Interest Expense TTM 44.2m)
EV/FCF = 65.67x (Enterprise Value 19.39b / FCF TTM 295.3m)
FCF Yield = 1.52% (FCF TTM 295.3m / Enterprise Value 19.39b)
FCF Margin = 9.23% (FCF TTM 295.3m / Revenue TTM 3.20b)
Net Margin = 10.29% (Net Income TTM 329.0m / Revenue TTM 3.20b)
Gross Margin = 22.87% ((Revenue TTM 3.20b - Cost of Revenue TTM 2.47b) / Revenue TTM)
Gross Margin QoQ = 20.98% (prev 21.82%)
Tobins Q-Ratio = 4.54 (Enterprise Value 19.39b / Total Assets 4.27b)
Interest Expense / Debt = 0.52% (Interest Expense 10.5m / Debt 2.02b)
Taxrate = 7.22% (7.29m / 101.0m)
NOPAT = 410.4m (EBIT 442.3m * (1 - 7.22%))
Current Ratio = 2.32 (Total Current Assets 1.56b / Total Current Liabilities 672.0m)
Debt / Equity = 1.64 (Debt 2.02b / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 2.74 (Net Debt 1.51b / EBITDA 551.5m)
Debt / FCF = 5.12 (Net Debt 1.51b / FCF TTM 295.3m)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.21% (Net Income 329.0m / Total Assets 4.27b)
RoE = 27.65% (Net Income TTM 329.0m / Total Stockholder Equity 1.19b)
RoCE = 13.80% (EBIT 442.3m / Capital Employed (Equity 1.19b + L.T.Debt 2.02b))
RoIC = 14.90% (NOPAT 410.4m / Invested Capital 2.75b)
WACC = 8.78% (E(17.88b)/V(19.89b) * Re(9.72%) + D(2.02b)/V(19.89b) * Rd(0.52%) * (1-Tc(0.07)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.08%
[DCF] Terminal Value 78.76% ; FCFF base≈279.1m ; Y1≈344.3m ; Y5≈586.3m
[DCF] Fair Price = 76.92 (EV 8.55b - Net Debt 1.51b = Equity 7.03b / Shares 91.4m; r=8.78% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 61.76 | EPS CAGR: 12.69% | SUE: 4.0 | # QB: 12
Revenue Correlation: 91.47 | Revenue CAGR: 14.64% | SUE: 1.79 | # QB: 4
EPS next Quarter (2026-06-30): EPS=1.09 | Chg7d=+0.040 | Chg30d=+0.040 | Revisions Net=+4 | Analysts=7
EPS current Year (2026-12-31): EPS=4.59 | Chg7d=+0.296 | Chg30d=+0.282 | Revisions Net=+9 | Growth EPS=+14.5% | Growth Revenue=+17.4%
EPS next Year (2027-12-31): EPS=5.16 | Chg7d=+0.244 | Chg30d=+0.162 | Revisions Net=+4 | Growth EPS=+12.4% | Growth Revenue=+9.4%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.9% (Discount Rate 9.7% - Earnings Yield 1.8%)
[Growth] Growth Spread = +10.0% (Analyst 17.9% - Implied 7.9%)
P/E Forward = 49.0196
P/S = 5.5895
P/B = 15.2524
P/EG = 1.6728
Revenue TTM = 3.20b USD
EBIT TTM = 442.3m USD
EBITDA TTM = 551.5m USD
Long Term Debt = 2.02b USD (from longTermDebt, last quarter)
Short Term Debt = 8.80m USD (from shortTermDebt, last quarter)
Debt = 2.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.51b USD (from netDebt column, last quarter)
Enterprise Value = 19.39b USD (17.88b + Debt 2.02b - CCE 502.9m)
Interest Coverage Ratio = 10.01 (Ebit TTM 442.3m / Interest Expense TTM 44.2m)
EV/FCF = 65.67x (Enterprise Value 19.39b / FCF TTM 295.3m)
FCF Yield = 1.52% (FCF TTM 295.3m / Enterprise Value 19.39b)
FCF Margin = 9.23% (FCF TTM 295.3m / Revenue TTM 3.20b)
Net Margin = 10.29% (Net Income TTM 329.0m / Revenue TTM 3.20b)
Gross Margin = 22.87% ((Revenue TTM 3.20b - Cost of Revenue TTM 2.47b) / Revenue TTM)
Gross Margin QoQ = 20.98% (prev 21.82%)
Tobins Q-Ratio = 4.54 (Enterprise Value 19.39b / Total Assets 4.27b)
Interest Expense / Debt = 0.52% (Interest Expense 10.5m / Debt 2.02b)
Taxrate = 7.22% (7.29m / 101.0m)
NOPAT = 410.4m (EBIT 442.3m * (1 - 7.22%))
Current Ratio = 2.32 (Total Current Assets 1.56b / Total Current Liabilities 672.0m)
Debt / Equity = 1.64 (Debt 2.02b / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 2.74 (Net Debt 1.51b / EBITDA 551.5m)
Debt / FCF = 5.12 (Net Debt 1.51b / FCF TTM 295.3m)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.21% (Net Income 329.0m / Total Assets 4.27b)
RoE = 27.65% (Net Income TTM 329.0m / Total Stockholder Equity 1.19b)
RoCE = 13.80% (EBIT 442.3m / Capital Employed (Equity 1.19b + L.T.Debt 2.02b))
RoIC = 14.90% (NOPAT 410.4m / Invested Capital 2.75b)
WACC = 8.78% (E(17.88b)/V(19.89b) * Re(9.72%) + D(2.02b)/V(19.89b) * Rd(0.52%) * (1-Tc(0.07)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.08%
[DCF] Terminal Value 78.76% ; FCFF base≈279.1m ; Y1≈344.3m ; Y5≈586.3m
[DCF] Fair Price = 76.92 (EV 8.55b - Net Debt 1.51b = Equity 7.03b / Shares 91.4m; r=8.78% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 61.76 | EPS CAGR: 12.69% | SUE: 4.0 | # QB: 12
Revenue Correlation: 91.47 | Revenue CAGR: 14.64% | SUE: 1.79 | # QB: 4
EPS next Quarter (2026-06-30): EPS=1.09 | Chg7d=+0.040 | Chg30d=+0.040 | Revisions Net=+4 | Analysts=7
EPS current Year (2026-12-31): EPS=4.59 | Chg7d=+0.296 | Chg30d=+0.282 | Revisions Net=+9 | Growth EPS=+14.5% | Growth Revenue=+17.4%
EPS next Year (2027-12-31): EPS=5.16 | Chg7d=+0.244 | Chg30d=+0.162 | Revisions Net=+4 | Growth EPS=+12.4% | Growth Revenue=+9.4%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.9% (Discount Rate 9.7% - Earnings Yield 1.8%)
[Growth] Growth Spread = +10.0% (Analyst 17.9% - Implied 7.9%)